New hope for kids with tough cancers: experimental drug targets genetic flaws
Disease control
Recruiting now
This study is testing a new drug called repotrectinib in children and young adults (up to age 25) with advanced or spreading cancers that have specific genetic changes (ALK, ROS1, or NTRK). The first part aims to find a safe dose. The second part will see if the drug can shrink t…
Phase: PHASE1, PHASE2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC